Objective To evaluate treatment with methotrexate (MTX) in patients with newly diagnosed
giant cell arteritis (GCA) to determine if MTX reduces GCA relapses and cumulative …

Background In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced
disease activity in patients with rheumatoid arthritis who had not previously received …

In a six-month, randomized, double-blind study at 14 centers, auranofin (3 mg twice daily)
was compared with placebo in the treatment of patients with classic or definite rheumatoid …

Objectives This study compared the efficacy and safety of subcutaneous (SC) versus
intravenous (IV) formulations of tocilizumab in patients with rheumatoid arthritis with an …

Objectives To evaluate the long-term efficacy and safety of subcutaneous (SC) tocilizumab
(TCZ) versus intravenous (IV) TCZ, including switching formulations, in patients with …

Background In ph 2 studies, baricitinib (bari) improved disease activity with an acceptable
safety profile in patients (pts) with active RA naïve to biologic DMARDs (bDMARDs). 1, 2 …

Objective To evaluate the impact of concomitant methotrexate (MTX) on subcutaneous (SC)
abatacept immunogenicity, and to assess safety and efficacy. Methods This phase III, open …

Objectives To assess the effect of a temporary interruption in subcutaneous (SC) abatacept
on immunogenicity, safety and efficacy in patients with active rheumatoid arthritis despite …

Apatite crystals can be associated with erosive arthritis. This report describes 3 such
patients, 2 of whom had idiopathic apatite crystal deposition and 1 who had apatite related …

Objective. To compare the clinical efficacy, effect on serum C‐reactive protein (CRP), serum
amyloid A (SAA), and plasma interleukin‐6 (IL‐6) levels, and safety of tenidap with a …